The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis.
Outcome measures to assess therapeutic interventions in cystic fibrosis (CF) patients with mild lung disease are lacking. Our aim was to determine if the lung clearance index (LCI) can detect a treatment response to dornase alfa in paediatric CF patients with normal spirometry. CF patients between 6-18 yrs of age with FEV(1 )≥ 80% pred were eligible. In a crossover design, 17 patients received 4 weeks of dornase alfa and placebo in a randomised sequence separated by a 4-week washout period. The primary end-point was the change in LCI from dornase alfa versus placebo. A mixed model approach incorporating period-dependent baselines was used. The mean ± sd age was 10.32 ± 3.35 yrs. Dornase alfa improved LCI versus placebo (0.90 ± 1.44; p = 0.022). Forced expiratory flow at 25-75% expired volume measured by % pred and z-scores also improved in subjects on dornase alfa (6.1% ± 10.34%; p = 0.03 and 0.28 ± 0.46 z-score; p = 0.03). Dornase alfa significantly improved LCI. Therefore the LCI may be a suitable tool to assess early intervention strategies in this patient population.
Amin
R
R
Division of Respiratory Medicine, Dept of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada. reshma.amin@sickkids.ca
Subbarao
P
P
Lou
W
W
Jabar
A
A
Balkovec
S
S
Jensen
R
R
Kerrigan
S
S
Gustafsson
P
P
Ratjen
F
F
D000293:Adolescent; D016956:Burkholderia cepacia / Q000378:metabolism; D002648:Child; D018592:Cross-Over Studies; D003550:Cystic Fibrosis / Q000188:drug therapy*; D003850:Deoxyribonuclease I / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008168:Lung / Q000473:pathology; D008297:Male; D010919:Placebos; D012107:Research Design; D012129:Respiratory Function Tests; D013147:Spirometry / Q000379:methods; D013997:Time Factors; D014691:Ventilation
D010919:Placebos; C085693:DNASE1 protein, human; D003850:Deoxyribonuclease I